Kintara Therapeutics Inc. (KTRA) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
10500 UNIVERSITY CENTER DR. TAMPA, FL 33612 |
| State of Incorp. | NV |
| Fiscal Year End | June 30 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)Annual | Quarterly
| 9/30/2024 Q1 | 6/30/2024 Q4 | 3/31/2024 Q3 | 12/31/2023 Q2 | 9/30/2023 Q1 | 6/30/2023 Q4 | 3/31/2023 Q3 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 4,909,000 | 6,351,000 | 658,000 | 216,000 | 1,535,000 | 3,045,000 | |||
| Cash and cash equivalents | 4,909,000 | 6,351,000 | 658,000 | 216,000 | 1,535,000 | 3,045,000 | |||
| Prepaid expense | 414,000 | 208,000 | 311,000 | 567,000 | 660,000 | 821,000 | |||
| Other undisclosed current assets | 205,000 | 196,000 | 217,000 | 1,075,000 | 2,150,000 | ||||
| Total current assets: | 5,528,000 | 6,755,000 | 1,186,000 | 783,000 | 3,270,000 | 6,016,000 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 674,000 | 691,000 | 699,000 | 694,000 | 709,000 | 724,000 | |||
| Total noncurrent assets: | 674,000 | 691,000 | 699,000 | 694,000 | 709,000 | 724,000 | |||
| TOTAL ASSETS: | 6,202,000 | 7,446,000 | 1,885,000 | 1,477,000 | 3,979,000 | 6,740,000 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 2,207,000 | 1,243,000 | 1,722,000 | 2,998,000 | 2,784,000 | 2,610,000 | |||
| Accounts payable | |||||||||
| Accrued liabilities | |||||||||
| Other undisclosed accounts payable and accrued liabilities | 2,207,000 | 1,243,000 | 1,722,000 | 2,998,000 | 2,784,000 | 2,610,000 | |||
| Other liabilities | 52,000 | ||||||||
| Due to related parties | ✕ | ✕ | ✕ | ✕ | ✕ | 298,000 | 180,000 | ||
| Other undisclosed current liabilities | 98,000 | 148,000 | 338,000 | ||||||
| Total current liabilities: | 2,259,000 | 1,341,000 | 1,870,000 | 3,336,000 | 3,082,000 | 2,790,000 | |||
| Noncurrent Liabilities | |||||||||
| Other undisclosed noncurrent liabilities | 186,000 | 183,000 | 179,000 | 167,000 | 166,000 | 164,000 | |||
| Total noncurrent liabilities: | 186,000 | 183,000 | 179,000 | 167,000 | 166,000 | 164,000 | |||
| Total liabilities: | 2,445,000 | 1,524,000 | 2,049,000 | 3,503,000 | 3,248,000 | 2,954,000 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | 3,757,000 | 5,922,000 | (164,000) | (2,026,000) | 731,000 | 3,786,000 | |||
| Common stock | 55,000 | 55,000 | 10,000 | 2,000 | 2,000 | 2,000 | |||
| Additional paid in capital | 153,305,000 | 153,144,000 | 145,090,000 | 141,855,000 | 141,438,000 | 141,156,000 | |||
| Accumulated other comprehensive income | 21,000 | 21,000 | 21,000 | 21,000 | 21,000 | 21,000 | |||
| Accumulated deficit | (159,876,000) | (157,550,000) | (155,537,000) | (154,512,000) | (151,375,000) | (148,038,000) | |||
| Stockholders' equity note, subscriptions receivable | (103,000) | ||||||||
| Other undisclosed equity, attributable to parent | 10,252,000 | 10,252,000 | 10,355,000 | 10,608,000 | 10,645,000 | 10,645,000 | |||
| Total equity: | 3,757,000 | 5,922,000 | (164,000) | (2,026,000) | 731,000 | 3,786,000 | |||
| TOTAL LIABILITIES AND EQUITY: | 6,202,000 | 7,446,000 | 1,885,000 | 1,477,000 | 3,979,000 | 6,740,000 | |||
Income Statement (P&L) (USD)Annual | Quarterly
| 9/30/2024 Q1 | 6/30/2024 Q4 | 3/31/2024 Q3 | 12/31/2023 Q2 | 9/30/2023 Q1 | 6/30/2023 Q4 | 3/31/2023 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (2,385,000) | (2,085,000) | (1,019,000) | (2,962,000) | (3,349,000) | (3,302,000) | ||
| Other operating income, net | 139,000 | 2,000 | ||||||
| Operating loss: | (2,246,000) | (2,085,000) | (1,019,000) | (2,960,000) | (3,349,000) | (3,302,000) | ||
| Nonoperating income (expense) | 61,000 | 74,000 | (4,000) | (2,000) | 14,000 | 38,000 | ||
| Loss, foreign currency transaction, before tax | (6,000) | (2,000) | (1,000) | |||||
| Loss from continuing operations: | (2,185,000) | (2,011,000) | (1,023,000) | (2,962,000) | (3,335,000) | (3,264,000) | ||
| Other undisclosed net loss | (139,000) | |||||||
| Net loss attributable to parent: | (2,324,000) | (2,011,000) | (1,023,000) | (2,962,000) | (3,335,000) | (3,264,000) | ||
| Preferred stock dividends and other adjustments | ||||||||
| Other undisclosed net loss available to common stockholders, basic | (2,000) | (2,000) | (2,000) | (175,000) | (2,000) | (2,000) | ||
| Net loss available to common stockholders, diluted: | (2,326,000) | (2,013,000) | (1,025,000) | (3,137,000) | (3,337,000) | (3,266,000) | ||
Comprehensive Income (USD)Annual | Quarterly
| 9/30/2024 Q1 | 6/30/2024 Q4 | 3/31/2024 Q3 | 12/31/2023 Q2 | 9/30/2023 Q1 | 6/30/2023 Q4 | 3/31/2023 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (2,324,000) | (2,011,000) | (1,023,000) | (2,962,000) | (3,335,000) | (3,264,000) | ||
| Comprehensive loss, net of tax, attributable to parent: | (2,324,000) | (2,011,000) | (1,023,000) | (2,962,000) | (3,335,000) | (3,264,000) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.